Skip to main content
. 2022 Jan 18;11:796197. doi: 10.3389/fonc.2021.796197

Figure 4.

Figure 4

(A) Baseline, left, MRI post contrast T1 Fat Sat demonstrating 18 × 9 mm right medial extraconal orbital peripherally enhancing mass. (B) MRI post contrast T1 Fat Sat, post five cycles of pembrolizumab 200 mg/3-weekly, no mass like enhancement.